Sigilon Therapeutics, Inc. announced that as previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the ?SEC?) by Sigilon Therapeutics, Inc. (the ?Company?), on June 28, 2023, the Company entered into an Agreement and Plan of Merger (the ?Merger Agreement?) with Eli Lilly and Company (?Parent?), and Parent?s wholly owned subsidiary, Shenandoah Acquisition Corporation (?Purchaser?). In accordance with the Merger Agreement, at the Effective Time, each of the directors of the Company (Rogerio Vivaldi Coelho, M.D., Douglas G. Cole, M.D., John Cox, Stephen N. Oesterle, M.D., Kavita Patel, M.D., Robert R. Ruffolo, Jr., Ph.D. and Eric D. Shaff) resigned as directors of the Company. These resignations were in connection with the Merger and not as a result of any disagreements between the Company and the resigning individuals on any matters related to the Company?s operations, policies or practices.

As of the Effective Time, in accordance with the Merger Agreement, Philip L. Johnson, Gordon J. Brooks, Michael C. Thompson, the directors of Purchaser immediately prior to the Effective Time, became directors of the Company. As of the Effective Time, in accordance with the Merger Agreement, Philip L. Johnson as President, Michael C. Thompson as Treasurer, Katie Lodato as Assistant Treasurer, Christopher Anderson as Secretary, and Jonathan Groff as Assistant Secretary, the executive officers of Purchaser immediately prior to the Effective Time, became the executive officers of the Company.